Extracellular matrix structure

Advanced Drug Delivery Reviews

Volumn 97, Issue , 2016, Pages 4-27

  Theocharis, Achilleas D ^a   Skandalis, Spyros S ^a   Gialeli, Chrysostomi ^a,b   Karamanos, Nikos K ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Cancer; Collagen; Extracellular matrix; Glycosaminoglycans; Integrins; Matrix metalloproteases; Pharmacological targeting; Proteoglycans

Indexed keywords

CELL ADHESION; CELL MEMBRANES; CELLS; COLLAGEN; CYTOLOGY; GLYCOPROTEINS; MACROMOLECULES;

CANCER; EXTRACELLULAR MATRICES; GLYCOSAMINOGLYCANS; INTEGRINS; METALLOPROTEASES; PHARMACOLOGICAL TARGETING; PROTEOGLYCANS;

COMPLEX NETWORKS;

CATHEPSIN; CELL SURFACE RECEPTOR; COLLAGEN; DISCOIDIN; ELASTIN; FIBRONECTIN; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; HERMES ANTIGEN; HYALURONIC ACID; IMATINIB; INTEGRIN; LAMININ; MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN; PROTEOGLYCAN; RONEPARSTAT; SCLEROPROTEIN;

CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; DRUG EFFECT; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; RECEPTORS, CELL SURFACE;

EID: 84957808678     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.11.001     Document Type: Review

References (377)

1. Frantz C., Stewart K.M., Weaver V.M. The extracellular matrix at a glance. J. Cell Sci. 2010, 123:4195-4200.
2. Clause K.C., Barker T.H. Extracellular matrix signaling in morphogenesis and repair. Curr. Opin. Biotechnol. 2013, 24:830-833.
3. Theocharis A.D., Gialeli C., Hascall V.C., Karamanos N.K. Extracellular matrix: a functional scaffold. Extracellular Matrix: Pathobiology and Signaling 2012, 3-20. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
4. LeBleu V.S., Macdonald B., Kalluri R. Structure and function of basement membranes. Exp. Biol. Med. 2007, 232:1121-1129.
5. Halfter W., Oertle P., Monnier C.A., Camenzind L., Reyes-Lua M., Hu H., Candiello J., Labilloy A., Balasubramani M., Henrich P.B., Plodinec M. New concepts in basement membrane biology. FEBS J. 2015, 10.1111/febs.13495.
6. Behrens D.T., Villone D., Koch M., Brunner G., Sorokin L., Robenek H., Bruckner-Tuderman L., Bruckner P., Hansen U. The epidermal basement membrane is a composite of separate laminin- or collagen IV-containing networks connected by aggregated perlecan, but not by nidogens. J. Biol. Chem. 2012, 287:18700-18709.
7. Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit. Rev. Biochem. Mol. Biol. 1992, 27:93-127.
8. Kirkpatrick C.A., Selleck S.B. Heparan sulfate proteoglycans at a glance. J. Cell Sci. 2007, 120:1829-1832.
9. Rozario T., DeSimone D.W. The extracellular matrix in development and morphogenesis: a dynamic view. Dev. Biol. 2010, 341:126-140.
10. Jarvelainen H., Sainio A., Koulu M., Wight T.N., Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol. Rev. 2009, 61:198-223.
11. Vlodavsky I., Iozzo R.V., Sanderson R.D. Heparanase: multiple functions in inflammation, diabetes and atherosclerosis. Matrix Biol. 2013, 32:220-222.
12. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
13. Bonnans C., Chou J., Werb Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 2014, 15:786-801.
14. Theocharis A.D., Skandalis S.S., Tzanakakis G.N., Karamanos N.K. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010, 277:3904-3923.
15. Afratis N., Gialeli C., Nikitovic D., Tsegenidis T., Karousou E., Theocharis A.D., Pavao M.S., Tzanakakis G.N., Karamanos N.K. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J. 2012, 279:1177-1197.
16. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 2011, 15:1013-1031.
17. Iozzo R.V., Schaefer L. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 2015, 42:11-55.
18. Theocharis A.D., Gialeli C., Bouris P., Giannopoulou E., Skandalis S.S., Aletras A.J., Iozzo R.V., Karamanos N.K. Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer. FEBS J. 2014, 281:5023-5042.
19. Theocharis A.D., Skandalis S.S., Neill T., Multhaupt H.A., Hubo M., Frey H., Gopal S., Gomes A., Afratis N., Lim H.C., Couchman J.R., Filmus J., Ralph D.S., Schaefer L., Iozzo R.V., Karamanos N.K. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim. Biophys. Acta 2015, 1855:276-300.
20. Karamanos N.K., Passi A. Novel insights into matrix pathobiology regulatory mechanisms in health and disease. FEBS J. 2014, 281:4978-4979.
21. Vigetti D., Viola M., Karousou E., Deleonibus S., Karamanou K., De Luca G., Passi A. Epigenetics in extracellular matrix remodeling and hyaluronan metabolism. FEBS J. 2014, 281:4980-4992.
22. Heldin P., Pertoft H. Synthesis and assembly of the hyaluronan-containing coats around normal human mesothelial cells. Exp. Cell Res. 1993, 208:422-429.
23. Laurent T.C., Fraser J.R. Hyaluronan. FASEB J. 1992, 6:2397-2404.
24. Weigel P.H. Functional characteristics and catalytic mechanisms of the bacterial hyaluronan synthases. IUBMB Life 2002, 54:201-211.
25. DeAngelis P.L., Jing W., Graves M.V., Burbank D.E., Van Etten J.L. Hyaluronan synthase of chlorella virus PBCV-1. Science 1997, 278:1800-1803.
26. Knudson C.B., Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J. 1993, 7:1233-1241.
27. Hascall V.C., Majors A.K., De La Motte C.A., Evanko S.P., Wang A., Drazba J.A., Strong S.A., Wight T.N. Intracellular hyaluronan: a new frontier for inflammation?. Biochim. Biophys. Acta 2004, 1673:3-12.
28. Li Y., Li L., Brown T.J., Heldin P. Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int. J. Cancer 2007, 120:2557-2567.
29. Toole B.P. Hyaluronan and its binding proteins, the hyaladherins. Curr. Opin. Cell Biol. 1990, 2:839-844.
30. Turley E.A., Noble P.W., Bourguignon L.Y. Signaling properties of hyaluronan receptors. J. Biol. Chem. 2002, 277:4589-4592.
31. Wu Y.J., La Pierre D.P., Wu J., Yee A.J., Yang B.B. The interaction of versican with its binding partners. Cell Res. 2005, 15:483-494.
32. Passi A., De Luca G., Karousou E., Vigetti D., Viola M. Metabolic control of hyaluronan synthesis. Extracellular Matrix: Pathobiology and Signaling 2012, 26-38. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
33. Jacobson A., Brinck J., Briskin M.J., Spicer A.P., Heldin P. Expression of human hyaluronan synthases in response to external stimuli. Biochem. J. 2000, 348(Pt 1):29-35.
34. Itano N., Sawai T., Yoshida M., Lenas P., Yamada Y., Imagawa M., Shinomura T., Hamaguchi M., Yoshida Y., Ohnuki Y., Miyauchi S., Spicer A.P., McDonald J.A., Kimata K. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J. Biol. Chem. 1999, 274:25085-25092.
35. Stern R., Jedrzejas M.J. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem. Rev. 2006, 106:818-839.
36. Aspberg A., Miura R., Bourdoulous S., Shimonaka M., Heinegard D., Schachner M., Ruoslahti E., Yamaguchi Y. The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:10116-10121.
37. Theocharis A.D. Versican in health and disease. Connect. Tissue Res. 2008, 49:230-234.
38. Mukhopadhyay A., Nikopoulos K., Maugeri A., de Brouwer A.P., van Nouhuys C.E., Boon C.J., Perveen R., Zegers H.A., Wittebol-Post D., van den Biesen P.R., van der Velde-Visser S.D., Brunner H.G., Black G.C., Hoyng C.B., Cremers F.P. Erosive vitreoretinopathy and wagner disease are caused by intronic mutations in CSPG2/Versican that result in an imbalance of splice variants. Invest. Ophthalmol. Vis. Sci. 2006, 47:3565-3572.
39. Kischel P., Waltregny D., Dumont B., Turtoi A., Greffe Y., Kirsch S., De Pauw E., Castronovo V. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int. J. Cancer 2010, 126:640-650.
40. Wight T.N., Kang I., Merrilees M.J. Versican and the control of inflammation. Matrix Biol. 2014, 35:152-161.
41. Wight T.N., Kinsella M.G., Evanko S.P., Potter-Perigo S., Merrilees M.J. Versican and the regulation of cell phenotype in disease. Biochim. Biophys. Acta 2014, 1840:2441-2451.
42. Kim S., Takahashi H., Lin W.W., Descargues P., Grivennikov S., Kim Y., Luo J.L., Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
43. Liu B.P., Cafferty W.B., Budel S.O., Strittmatter S.M. Extracellular regulators of axonal growth in the adult central nervous system. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 2006, 361:1593-1610.
44. Davies J.E., Tang X., Denning J.W., Archibald S.J., Davies S.J. Decorin suppresses neurocan, brevican, phosphacan and NG2 expression and promotes axon growth across adult rat spinal cord injuries. Eur. J. Neurosci. 2004, 19:1226-1242.
45. Lu R., Wu C., Guo L., Liu Y., Mo W., Wang H., Ding J., Wong E.T., Yu M. The role of brevican in glioma: promoting tumor cell motility in vitro and in vivo. BMC Cancer 2012, 12:607.
46. Dwyer C.A., Bi W.L., Viapiano M.S., Matthews R.T. Brevican knockdown reduces late-stage glioma tumor aggressiveness. J. Neuro-Oncol. 2014, 120:63-72.
47. Chen S., Birk D.E. The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly. FEBS J. 2013, 280:2120-2137.
48. Reese S.P., Underwood C.J., Weiss J.A. Effects of decorin proteoglycan on fibrillogenesis, ultrastructure, and mechanics of type I collagen gels. Matrix Biol. 2013, 32:414-423.
49. Dunkman A.A., Buckley M.R., Mienaltowski M.J., Adams S.M., Thomas S.J., Satchell L., Kumar A., Pathmanathan L., Beason D.P., Iozzo R.V., Birk D.E., Soslowsky L.J. Decorin expression is important for age-related changes in tendon structure and mechanical properties. Matrix Biol. 2013, 32:3-13.
50. Chen S., Young M.F., Chakravarti S., Birk D.E. Interclass small leucine-rich repeat proteoglycan interactions regulate collagen fibrillogenesis and corneal stromal assembly. Matrix Biol. 2014, 35:103-111.
51. Iozzo R.V., Moscatello D.K., McQuillan D.J., Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J. Biol. Chem. 1999, 274:4489-4492.
52. Goldoni S., Humphries A., Nystrom A., Sattar S., Owens R.T., McQuillan D.J., Ireton K., Iozzo R.V. Decorin is a novel antagonistic ligand of the Met receptor. J. Cell Biol. 2009, 185:743-754.
53. Morcavallo A., Buraschi S., Xu S.Q., Belfiore A., Schaefer L., Iozzo R.V., Morrione A. Decorin differentially modulates the activity of insulin receptor isoform A ligands. Matrix Biol. 2014, 35:82-90.
54. Horvath Z., Kovalszky I., Fullar A., Kiss K., Schaff Z., Iozzo R.V., Baghy K. Decorin deficiency promotes hepatic carcinogenesis. Matrix Biol. 2014, 35:194-205.
55. Merline R., Moreth K., Beckmann J., Nastase M.V., Zeng-Brouwers J., Tralhao J.G., Lemarchand P., Pfeilschifter J., Schaefer R.M., Iozzo R.V., Schaefer L. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci. Signal. 2011, 4:ra75.
56. Schaefer L., Iozzo R.V. Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr. Opin. Genet. Dev. 2012, 22:56-57.
57. Skandalis S.S., Afratis N., Smirlaki G., Nikitovic D., Theocharis A.D., Tzanakakis G.N., Karamanos N.K. Cross-talk between estradiol receptor and EGFR/IGF-IR signaling pathways in estrogen-responsive breast cancers: focus on the role and impact of proteoglycans. Matrix Biol. 2014, 35:182-193.
58. Nikolovska K., Renke J.K., Jungmann O., Grobe K., Iozzo R.V., Zamfir A.D., Seidler D.G. A decorin-deficient matrix affects skin chondroitin/dermatan sulfate levels and keratinocyte function. Matrix Biol. 2014, 35:91-102.
59. Vesentini S., Redaelli A., Montevecchi F.M. Estimation of the binding force of the collagen molecule-decorin core protein complex in collagen fibril. J. Biomech. 2005, 38:433-443.
60. Bredrup C., Knappskog P.M., Majewski J., Rodahl E., Boman H. Congenital stromal dystrophy of the cornea caused by a mutation in the decorin gene. Invest. Ophthalmol. Vis. Sci. 2005, 46:420-426.
61. Kim J.H., Ko J.M., Lee I., Kim J.Y., Kim M.J., Tchah H. A novel mutation of the decorin gene identified in a Korean family with congenital hereditary stromal dystrophy. Cornea 2011, 30:1473-1477.
62. Yamaguchi Y., Mann D.M., Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990, 346:281-284.
63. De Luca A., Santra M., Baldi A., Giordano A., Iozzo R.V. Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem. 1996, 271:18961-18965.
64. Moscatello D.K., Santra M., Mann D.M., McQuillan D.J., Wong A.J., Iozzo R.V. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J. Clin. Invest. 1998, 101:406-412.
65. Zhu J.X., Goldoni S., Bix G., Owens R.T., McQuillan D.J., Reed C.C., Iozzo R.V. Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J. Biol. Chem. 2005, 280:32468-32479.
66. Csordas G., Santra M., Reed C.C., Eichstetter I., McQuillan D.J., Gross D., Nugent M.A., Hajnoczky G., Iozzo R.V. Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J. Biol. Chem. 2000, 275:32879-32887.
67. Buraschi S., Pal N., Tyler-Rubinstein N., Owens R.T., Neill T., Iozzo R.V. Decorin antagonizes Met receptor activity and down-regulates β-catenin and Myc levels. J. Biol. Chem. 2010, 285:42075-42085.
68. Neill T., Painter H., Buraschi S., Owens R.T., Lisanti M.P., Schaefer L., Iozzo R.V. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1alpha, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J. Biol. Chem. 2012, 287:5492-5506.
69. Neill T., Jones H.R., Crane-Smith Z., Owens R.T., Schaefer L., Iozzo R.V. Decorin induces rapid secretion of thrombospondin-1 in basal breast carcinoma cells via inhibition of Ras homolog gene family, member A/Rho-associated coiled-coil containing protein kinase 1. FEBS J. 2013, 280:2353-2368.
70. Morrione A., Neill T., Iozzo R.V. Dichotomy of decorin activity on the insulin-like growth factor-I system. FEBS J. 2013, 280:2138-2149.
71. Buraschi S., Neill T., Goyal A., Poluzzi C., Smythies J., Owens R.T., Schaefer L., Torres A., Iozzo R.V. Decorin causes autophagy in endothelial cells via Peg3. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E2582-E2591.
72. Jarvelainen H., Sainio A., Wight T.N. Pivotal role for decorin in angiogenesis. Matrix Biol. 2015, 43:15-26.
73. Neill T., Schaefer L., Iozzo R.V. Instructive roles of extracellular matrix on autophagy. Am. J. Pathol. 2014, 184:2146-2153.
74. Xu T., Bianco P., Fisher L.W., Longenecker G., Smith E., Goldstein S., Bonadio J., Boskey A., Heegaard A.M., Sommer B., Satomura K., Dominguez P., Zhao C., Kulkarni A.B., Robey P.G., Young M.F. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 1998, 20:78-82.
75. Kolb M., Margetts P.J., Sime P.J., Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280:L1327-L1334.
76. Berendsen A.D., Pinnow E.L., Maeda A., Brown A.C., McCartney-Francis N., Kram V., Owens R.T., Robey P.G., Holmbeck K., de Castro L.F., Kilts T.M., Young M.F. Biglycan modulates angiogenesis and bone formation during fracture healing. Matrix Biol. 2014, 35:223-231.
77. Schaefer L., Babelova A., Kiss E., Hausser H.J., Baliova M., Krzyzankova M., Marsche G., Young M.F., Mihalik D., Gotte M., Malle E., Schaefer R.M., Grone H.J. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 2005, 115:2223-2233.
78. Babelova A., Moreth K., Tsalastra-Greul W., Zeng-Brouwers J., Eickelberg O., Young M.F., Bruckner P., Pfeilschifter J., Schaefer R.M., Grone H.J., Schaefer L. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem. 2009, 284:24035-24048.
79. Sjoberg A., Onnerfjord P., Morgelin M., Heinegard D., Blom A.M. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J. Biol. Chem. 2005, 280:32301-32308.
80. Oldberg A., Kalamajski S., Salnikov A.V., Stuhr L., Morgelin M., Reed R.K., Heldin N.E., Rubin K. Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13966-13971.
81. Jian J., Zheng Z., Zhang K., Rackohn T.M., Hsu C., Levin A., Enjamuri D.R., Zhang X., Ting K., Soo C. Fibromodulin promoted in vitro and in vivo angiogenesis. Biochem. Biophys. Res. Commun. 2013, 436:530-535.
82. Adini I., Ghosh K., Adini A., Chi Z.L., Yoshimura T., Benny O., Connor K.M., Rogers M.S., Bazinet L., Birsner A.E., Bielenberg D.R., D'Amato R.J. Melanocyte-secreted fibromodulin promotes an angiogenic microenvironment. J. Clin. Invest. 2014, 124:425-436.
83. Leygue E., Snell L., Dotzlaw H., Troup S., Hiller-Hitchcock T., Murphy L.C., Roughley P.J., Watson P.H. Lumican and decorin are differentially expressed in human breast carcinoma. J. Pathol. 2000, 192:313-320.
84. Sifaki M., Assouti M., Nikitovic D., Krasagakis K., Karamanos N.K., Tzanakakis G.N. Lumican, a small leucine-rich proteoglycan substituted with keratan sulfate chains is expressed and secreted by human melanoma cells and not normal melanocytes. IUBMB Life 2006, 58:606-610.
85. Brezillon S., Venteo L., Ramont L., D'Onofrio M.F., Perreau C., Pluot M., Maquart F.X., Wegrowski Y. Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma. Clin. Exp. Dermatol. 2007, 32:405-416.
86. D'Onofrio M.F., Brezillon S., Baranek T., Perreau C., Roughley P.J., Maquart F.X., Wegrowski Y. Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican. Biochem. Biophys. Res. Commun. 2008, 365:266-272.
87. Brezillon S., Radwanska A., Zeltz C., Malkowski A., Ploton D., Bobichon H., Perreau C., Malicka-Blaszkiewicz M., Maquart F.X., Wegrowski Y. Lumican core protein inhibits melanoma cell migration via alterations of focal adhesion complexes. Cancer Lett. 2009, 283:92-100.
88. Nikitovic D., Papoutsidakis A., Karamanos N.K., Tzanakakis G.N. Lumican affects tumor cell functions, tumor-ECM interactions, angiogenesis and inflammatory response. Matrix Biol. 2014, 35:206-214.
89. Nikitovic D., Berdiaki A., Zafiropoulos A., Katonis P., Tsatsakis A., Karamanos N.K., Tzanakakis G.N. Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells. FEBS J. 2008, 275:350-361.
90. Nikitovic D., Chalkiadaki G., Berdiaki A., Aggelidakis J., Katonis P., Karamanos N.K., Tzanakakis G.N. Lumican regulates osteosarcoma cell adhesion by modulating TGFbeta2 activity. Int. J. Biochem. Cell Biol. 2011, 43:928-935.
91. Pietraszek K., Chatron-Colliet A., Brezillon S., Perreau C., Jakubiak-Augustyn A., Krotkiewski H., Maquart F.X., Wegrowski Y. Lumican: a new inhibitor of matrix metalloproteinase-14 activity. FEBS Lett. 2014, 588:4319-4324.
92. Willis C.D., Poluzzi C., Mongiat M., Iozzo R.V. Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells. FEBS J. 2013, 280:2271-2284.
93. Bix G., Castello R., Burrows M., Zoeller J.J., Weech M., Iozzo R.A., Cardi C., Thakur M.L., Barker C.A., Camphausen K., Iozzo R.V. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J. Natl. Cancer Inst. 2006, 98:1634-1646.
94. Mongiat M., Sweeney S.M., San Antonio J.D., Fu J., Iozzo R.V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 2003, 278:4238-4249.
95. Poluzzi C., Casulli J., Goyal A., Mercer T.J., Neill T., Iozzo R.V. Endorepellin evokes autophagy in endothelial cells. J. Biol. Chem. 2014, 289:16114-16128.
96. Smirnov S.P., Barzaghi P., McKee K.K., Ruegg M.A., Yurchenco P.D. Conjugation of LG domains of agrins and perlecan to polymerizing laminin-2 promotes acetylcholine receptor clustering. J. Biol. Chem. 2005, 280:41449-41457.
97. Huze C., Bauche S., Richard P., Chevessier F., Goillot E., Gaudon K., Ben Ammar A., Chaboud A., Grosjean I., Lecuyer H.A., Bernard V., Rouche A., Alexandri N., Kuntzer T., Fardeau M., Fournier E., Brancaccio A., Ruegg M.A., Koenig J., Eymard B., Schaeffer L., Hantai D. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am. J. Hum. Genet. 2009, 85:155-167.
98. Nicole S., Chaouch A., Torbergsen T., Bauche S., de Bruyckere E., Fontenille M.J., Horn M.A., van Ghelue M., Loseth S., Issop Y., Cox D., Muller J.S., Evangelista T., Stalberg E., Ioos C., Barois A., Brochier G., Sternberg D., Fournier E., Hantai D., Abicht A., Dusl M., Laval S.H., Griffin H., Eymard B., Lochmuller H. Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy. Brain 2014, 137:2429-2443.
99. Couchman J.R. Transmembrane signaling proteoglycans. Annu. Rev. Cell Dev. Biol. 2010, 26:89-114.
100. Xian X., Gopal S., Couchman J.R. Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res. 2010, 339:31-46.
101. Yoneda A., Couchman J.R. Regulation of cytoskeletal organization by syndecan transmembrane proteoglycans. Matrix Biol. 2003, 22:25-33.
102. Gotte M. Syndecans in inflammation. FASEB J. 2003, 17:575-591.
103. Alexopoulou A.N., Multhaupt H.A., Couchman J.R. Syndecans in wound healing, inflammation and vascular biology. Int. J. Biochem. Cell Biol. 2007, 39:505-528.
104. Tsonis A.I., Afratis N., Gialeli C., Ellina M.I., Piperigkou Z., Skandalis S.S., Theocharis A.D., Tzanakakis G.N., Karamanos N.K. Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin-like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells. FEBS J. 2013, 280:2248-2259.
105. Couchman J.R. Syndecans: proteoglycan regulators of cell-surface microdomains?. Nat. Rev. Mol. Cell Biol. 2003, 4:926-937.
106. Pataki C., Couchman J.R. Structure and function of syndecans. Extracellular Matrix: Pathobiology and Signaling 2012, 197-208. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
107. Zhang L., David G., Esko J.D. Repetitive Ser-Gly sequences enhance heparan sulfate assembly in proteoglycans. J. Biol. Chem. 1995, 270:27127-27135.
108. Multhaupt H.A., Yoneda A., Whiteford J.R., Oh E.S., Lee W., Couchman J.R. Syndecan signaling: when, where and why?. J. Physiol. Pharmacol. 2009, 60(Suppl. 4):31-38.
109. Yamashita H., Goto A., Kadowaki T., Kitagawa Y. Mammalian and Drosophila cells adhere to the laminin alpha4 LG4 domain through syndecans, but not glypicans. Biochem. J. 2004, 382:933-943.
110. Vuoriluoto K., Jokinen J., Kallio K., Salmivirta M., Heino J., Ivaska J. Syndecan-1 supports integrin alpha2beta1-mediated adhesion to collagen. Exp. Cell Res. 2008, 314:3369-3381.
111. Orend G., Huang W., Olayioye M.A., Hynes N.E., Chiquet-Ehrismann R. Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene 2003, 22:3917-3926.
112. Nunes S.S., Outeiro-Bernstein M.A., Juliano L., Vardiero F., Nader H.B., Woods A., Legrand C., Morandi V. Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1. J. Cell. Physiol. 2008, 214:828-837.
113. Xian X., Whiteford J.R., Couchman J.R. Syndecans as receptors for pericellular molecules. Extracellular Matrix: Pathobiology and Signaling 2012, 467-483. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
114. Yang Y., Yaccoby S., Liu W., Langford J.K., Pumphrey C.Y., Theus A., Epstein J., Sanderson R.D. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002, 100:610-617.
115. Sanderson R.D., Iozzo R.V. Targeting heparanase for cancer therapy at the tumor-matrix interface. Matrix Biol. 2012, 31:283-284.
116. Ramani V.C., Purushothaman A., Stewart M.D., Thompson C.A., Vlodavsky I., Au J.L., Sanderson R.D. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 2013, 280:2294-2306.
117. Peterson S.B., Liu J. Multi-faceted substrate specificity of heparanase. Matrix Biol. 2013, 32:223-227.
118. Purushothaman A., Uyama T., Kobayashi F., Yamada S., Sugahara K., Rapraeger A.C., Sanderson R.D. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115:2449-2457.
119. Filmus J., Capurro M., Rast J. Glypicans. Genome Biol. 2008, 9:224.
120. Filmus J., Capurro M. The glypican family. Extracellular Matrix: Pathobiology and Signaling 2012, 209-220. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
121. Song H.H., Filmus J. The role of glypicans in mammalian development. Biochim. Biophys. Acta 2002, 1573:241-246.
122. Saunders S., Paine-Saunders S., Lander A.D. Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain. Dev. Biol. 1997, 190:78-93.
123. Li F., Shi W., Capurro M., Filmus J. Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J. Cell Biol. 2011, 192:691-704.
124. Capurro M.I., Li F., Filmus J. Overgrowth of a mouse model of Simpson-Golabi-Behmel syndrome is partly mediated by Indian hedgehog. EMBO Rep. 2009, 10:901-907.
125. Capurro M.I., Xu P., Shi W., Li F., Jia A., Filmus J. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev. Cell 2008, 14:700-711.
126. You W.K., Yotsumoto F., Sakimura K., Adams R.H., Stallcup W.B. NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function. Angiogenesis 2014, 17:61-76.
127. Jovanovic B., Beeler J.S., Pickup M.W., Chytil A., Gorska A.E., Ashby W.J., Lehmann B.D., Zijlstra A., Pietenpol J.A., Moses H.L. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. Breast Cancer Res. 2014, 16:R69.
128. Elderbroom J.L., Huang J.J., Gatza C.E., Chen J., How T., Starr M., Nixon A.B., Blobe G.C. Ectodomain shedding of TbetaRIII is required for TbetaRIII-mediated suppression of TGF-beta signaling and breast cancer migration and invasion. Mol. Biol. Cell 2014, 25:2320-2332.
129. Theocharidis U., Long K., Ffrench-Constant C., Faissner A. Regulation of the neural stem cell compartment by extracellular matrix constituents. Prog. Brain Res. 2014, 214:3-28.
130. Kolset S.O., Pejler G. Serglycin: a structural and functional chameleon with wide impact on immune cells. J. Immunol. 2011, 187:4927-4933.
131. Korpetinou A., Milia-Argeiti E., Labropoulou V., Theocharis A.D. Serglycin: a novel player in the terrain of neoplasia. Extracellular Matrix: Pathobiology and Signaling 2012, 677-688. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
132. Korpetinou A., Skandalis S.S., Labropoulou V.T., Smirlaki G., Noulas A., Karamanos N.K., Theocharis A.D. Serglycin: at the crossroad of inflammation and malignancy. Front. Oncol. 2014, 3:327.
133. Korpetinou A., Skandalis S.S., Moustakas A., Happonen K.E., Tveit H., Prydz K., Labropoulou V.T., Giannopoulou E., Kalofonos H.P., Blom A.M., Karamanos N.K., Theocharis A.D. Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells. PLoS One 2013, 8.
134. Purushothaman A., Toole B.P. Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization. J. Biol. Chem. 2014, 289:5499-5509.
135. Theocharis A.D., Seidel C., Borset M., Dobra K., Baykov V., Labropoulou V., Kanakis I., Dalas E., Karamanos N.K., Sundan A., Hjerpe A. Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J. Biol. Chem. 2006, 281:35116-35128.
136. Skliris A., Labropoulou V.T., Papachristou D.J., Aletras A., Karamanos N.K., Theocharis A.D. Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases. FEBS J. 2013, 280:2342-2352.
137. Hamilton A., Basic V., Andersson S., Abrink M., Ringvall M. Loss of Serglycin Promotes Primary Tumor Growth and Vessel Functionality in the RIP1-Tag2 Mouse Model for Spontaneous Insulinoma Formation. PLoS One 2015, 10.
138. Skliris A., Happonen K.E., Terpos E., Labropoulou V., Borset M., Heinegard D., Blom A.M., Theocharis A.D. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma. Eur. J. Immunol. 2011, 41:437-449.
139. Kadler K.E., Baldock C., Bella J., Boot-Handford R.P. Collagens at a glance. J. Cell Sci. 2007, 120:1955-1958.
140. Heino J. The collagen family members as cell adhesion proteins. BioEssays 2007, 29:1001-1010.
141. Shoulders M.D., Raines R.T. Collagen structure and stability. Annu. Rev. Biochem. 2009, 78:929-958.
142. Payne L.S., Huang P.H. The pathobiology of collagens in glioma. Mol. Cancer Res. 2013, 11:1129-1140.
143. Corsi A., Xu T., Chen X.D., Boyde A., Liang J., Mankani M., Sommer B., Iozzo R.V., Eichstetter I., Robey P.G., Bianco P., Young M.F. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2002, 17:1180-1189.
144. Chessler S.D., Wallis G.A., Byers P.H. Mutations in the carboxyl-terminal propeptide of the pro alpha 1(I) chain of type I collagen result in defective chain association and produce lethal osteogenesis imperfecta. J. Biol. Chem. 1993, 268:18218-18225.
145. Pace J.M., Kuslich C.D., Willing M.C., Byers P.H. Disruption of one intra-chain disulphide bond in the carboxyl-terminal propeptide of the proalpha1(I) chain of type I procollagen permits slow assembly and secretion of overmodified, but stable procollagen trimers and results in mild osteogenesis imperfecta. J. Med. Genet. 2001, 38:443-449.
146. Myllyharju J., Kivirikko K.I. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet. 2004, 20:33-43.
147. Colige A., Ruggiero F., Vandenberghe I., Dubail J., Kesteloot F., Van Beeumen J., Beschin A., Brys L., Lapiere C.M., Nusgens B. Domains and maturation processes that regulate the activity of ADAMTS-2, a metalloproteinase cleaving the aminopropeptide of fibrillar procollagens types I-III and V. J. Biol. Chem. 2005, 280:34397-34408.
148. Boudko S.P., Bachinger H.P. Trimerization domains in collagens: chain selection, folding initiation, and triple-helix stabilization. Extracellular Matrix: Pathobiology and Signaling 2012, 506-520. Walter de Gruyter GmbH & Co. KG, Berlin/Boston.
149. Than M.E., Henrich S., Huber R., Ries A., Mann K., Kuhn K., Timpl R., Bourenkov G.P., Bartunik H.D., Bode W. The 1.9-A crystal structure of the noncollagenous (NC1) domain of human placenta collagen IV shows stabilization via a novel type of covalent Met-Lys cross-link. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6607-6612.
150. Bogin O., Kvansakul M., Rom E., Singer J., Yayon A., Hohenester E. Insight into Schmid metaphyseal chondrodysplasia from the crystal structure of the collagen X NC1 domain trimer. Structure 2002, 10:165-173.
151. Kvansakul M., Bogin O., Hohenester E., Yayon A. Crystal structure of the collagen alpha1(VIII) NC1 trimer. Matrix Biol. 2003, 22:145-152.
152. San Antonio J.D., Des Parkin J., Savige J., Orgel J.P.R.O., Jacenko O. Collagen interactomes: mapping functional domains and mutations on fibrillar and network-forming collagens. Extracellular Matrix: Pathobiology and Signaling 2012, 575-591. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
153. Wu J.J., Woods P.E., Eyre D.R. Identification of cross-linking sites in bovine cartilage type IX collagen reveals an antiparallel type II-type IX molecular relationship and type IX to type IX bonding. J. Biol. Chem. 1992, 267:23007-23014.
154. Huber S., van der Rest M., Bruckner P., Rodriguez E., Winterhalter K.H., Vaughan L. Identification of the type IX collagen polypeptide chains. The alpha 2(IX) polypeptide carries the chondroitin sulfate chain(s). J. Biol. Chem. 1986, 261:5965-5968.
155. Fassler R., Schnegelsberg P.N., Dausman J., Shinya T., Muragaki Y., McCarthy M.T., Olsen B.R., Jaenisch R. Mice lacking alpha 1 (IX) collagen develop noninflammatory degenerative joint disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5070-5074.
156. Von der Mark K. Structure, biosynthesis and gene regulation of collagens in cartilage and bone 2006, 3-40. Dynamics of Bone and Cartilage Metabolism Academic Press, New York. M.J. Seibel, S.P. Robins, J.P. Bilezikian (Eds.).
157. Franzke C.W., Tasanen K., Schacke H., Zhou Z., Tryggvason K., Mauch C., Zigrino P., Sunnarborg S., Lee D.C., Fahrenholz F., Bruckner-Tuderman L. Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J. 2002, 21:5026-5035.
158. Wagenseil J.E., Mecham R.P. New insights into elastic fiber assembly. Birth Defects Res. C Embryo Today 2007, 81:229-240.
159. Muiznieks L.D., Weiss A.S., Keeley F.W. Structural disorder and dynamics of elastin. Biochem. Cell Biol. 2010, 88:239-250.
160. Sengle G., Sakai L.Y. The fibrillin microfibril scaffold: a niche for growth factors and mechanosensation?. Matrix Biol. 2015, 47:3-12.
161. Downing A.K., Knott V., Werner J.M., Cardy C.M., Campbell I.D., Handford P.A. Solution structure of a pair of calcium-binding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorders. Cell 1996, 85:597-605.
162. Sakamoto H., Broekelmann T., Cheresh D.A., Ramirez F., Rosenbloom J., Mecham R.P. Cell-type specific recognition of RGD- and non-RGD-containing cell binding domains in fibrillin-1. J. Biol. Chem. 1996, 271:4916-4922.
163. Bax D.V., Bernard S.E., Lomas A., Morgan A., Humphries J., Shuttleworth C.A., Humphries M.J., Kielty C.M. Cell adhesion to fibrillin-1 molecules and microfibrils is mediated by alpha 5 beta 1 and alpha v beta 3 integrins. J. Biol. Chem. 2003, 278:34605-34616.
164. Tiedemann K., Batge B., Muller P.K., Reinhardt D.P. Interactions of fibrillin-1 with heparin/heparan sulfate, implications for microfibrillar assembly. J. Biol. Chem. 2001, 276:36035-36042.
165. Ritty T.M., Broekelmann T.J., Werneck C.C., Mecham R.P. Fibrillin-1 and -2 contain heparin-binding sites important for matrix deposition and that support cell attachment. Biochem. J. 2003, 375:425-432.
166. Mecham R.P., Gibson M.A. The microfibril-associated glycoproteins (MAGPs) and the microfibrillar niche. Matrix Biol. 2015, 47:13-33.
167. Papke C.L., Yanagisawa H. Fibulin-4 and fibulin-5 in elastogenesis and beyond: Insights from mouse and human studies. Matrix Biol. 2014, 37:142-149.
168. Danussi C., Petrucco A., Wassermann B., Pivetta E., Modica T.M., Del Bel Belluz L., Colombatti A., Spessotto P. EMILIN1-alpha4/alpha9 integrin interaction inhibits dermal fibroblast and keratinocyte proliferation. J. Cell Biol. 2011, 195:131-145.
169. Danussi C., Del Bel Belluz L., Pivetta E., Modica T.M., Muro A., Wassermann B., Doliana R., Sabatelli P., Colombatti A., Spessotto P. EMILIN1/alpha9beta1 integrin interaction is crucial in lymphatic valve formation and maintenance. Mol. Cell. Biol. 2013, 33:4381-4394.
170. Wells J.M., Gaggar A., Blalock J.E. MMP generated matrikines. Matrix Biol. 2015, 44-46C:122-129.
171. George E.L., Georges-Labouesse E.N., Patel-King R.S., Rayburn H., Hynes R.O. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993, 119:1079-1091.
172. Hynes R.O. Fibronectins. Sci. Am. 1986, 254:42-51.
173. Sasaki T. Collagen-binding proteins. Extracellular Matrix: Pathobiology and Signaling 2012, 592-602. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
174. Main A.L., Harvey T.S., Baron M., Boyd J., Campbell I.D. The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions. Cell 1992, 71:671-678.
175. Pankov R., Yamada K.M. Fibronectin at a glance. J. Cell Sci. 2002, 115:3861-3863.
176. Davidson L.A., Keller R., DeSimone D.W. Assembly and remodeling of the fibrillar fibronectin extracellular matrix during gastrulation and neurulation in Xenopus laevis. Dev. Dyn. 2004, 231:888-895.
177. Larsen M., Wei C., Yamada K.M. Cell and fibronectin dynamics during branching morphogenesis. J. Cell Sci. 2006, 119:3376-3384.
178. Moretti F.A., Chauhan A.K., Iaconcig A., Porro F., Baralle F.E., Muro A.F. A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived. J. Biol. Chem. 2007, 282:28057-28062.
179. Avnur Z., Geiger B. The removal of extracellular fibronectin from areas of cell-substrate contact. Cell 1981, 25:121-132.
180. Leikina E., Mertts M.V., Kuznetsova N., Leikin S. Type I collagen is thermally unstable at body temperature. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1314-1318.
181. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
182. Pierschbacher M.D., Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984, 309:30-33.
183. Wayner E.A., Garcia-Pardo A., Humphries M.J., McDonald J.A., Carter W.G. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J. Cell Biol. 1989, 109:1321-1330.
184. Guan J.L., Hynes R.O. Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. Cell 1990, 60:53-61.
185. Aota S., Nomizu M., Yamada K.M. The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J. Biol. Chem. 1994, 269:24756-24761.
186. Bowditch R.D., Hariharan M., Tominna E.F., Smith J.W., Yamada K.M., Getzoff E.D., Ginsberg M.H. Identification of a novel integrin binding site in fibronectin. Differential utilization by beta 3 integrins. J. Biol. Chem. 1994, 269:10856-10863.
187. Saunders S., Bernfield M. Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behaves as a receptor for interstitial matrix. J. Cell Biol. 1988, 106:423-430.
188. Woods A., Longley R.L., Tumova S., Couchman J.R. Syndecan-4 binding to the high affinity heparin-binding domain of fibronectin drives focal adhesion formation in fibroblasts. Arch. Biochem. Biophys. 2000, 374:66-72.
189. Barkalow F.J., Schwarzbauer J.E. Interactions between fibronectin and chondroitin sulfate are modulated by molecular context. J. Biol. Chem. 1994, 269:3957-3962.
190. Woods A., Couchman J.R. Syndecans: synergistic activators of cell adhesion. Trends Cell Biol. 1998, 8:189-192.
191. Morgan M.R., Humphries M.J., Bass M.D. Synergistic control of cell adhesion by integrins and syndecans. Nat. Rev. Mol. Cell Biol. 2007, 8:957-969.
192. Sottile J., Hocking D.C. Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol. Biol. Cell 2002, 13:3546-3559.
193. Wierzbicka-Patynowski I., Mao Y., Schwarzbauer J.E. Continuous requirement for pp 60-Src and phospho-paxillin during fibronectin matrix assembly by transformed cells. J. Cell. Physiol. 2007, 210:750-756.
194. Georges-Labouesse E.N., George E.L., Rayburn H., Hynes R.O. Mesodermal development in mouse embryos mutant for fibronectin. Dev. Dyn. 1996, 207:145-156.
195. Astrof S., Hynes R.O. Fibronectins in vascular morphogenesis. Angiogenesis 2009, 12:165-175.
196. Oyama F., Hirohashi S., Shimosato Y., Titani K., Sekiguchi K. Deregulation of alternative splicing of fibronectin pre-mRNA in malignant human liver tumors. J. Biol. Chem. 1989, 264:10331-10334.
197. Inufusa H., Nakamura M., Adachi T., Nakatani Y., Shindo K., Yasutomi M., Matsuura H. Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with histologic grade, liver metastasis, and prognosis. Cancer 1995, 75:2802-2808.
198. Wan A.M., Chandler E.M., Madhavan M., Infanger D.W., Ober C.K., Gourdon D., Malliaras G.G., Fischbach C. Fibronectin conformation regulates the proangiogenic capability of tumor-associated adipogenic stromal cells. Biochim. Biophys. Acta 2013, 1830:4314-4320.
199. Chandler E.M., Seo B.R., Califano J.P., Andresen Eguiluz R.C., Lee J.S., Yoon C.J., Tims D.T., Wang J.X., Cheng L., Mohanan S., Buckley M.R., Cohen I., Nikitin A.Y., Williams R.M., Gourdon D., Reinhart-King C.A., Fischbach C. Implanted adipose progenitor cells as physicochemical regulators of breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:9786-9791.
200. Durbeej M. Laminins. Cell Tissue Res. 2010, 339:259-268.
201. Iorio V., Troughton L.D., Hamill K.J. Laminins: roles and utility in wound repair. Adv. Wound Care 2015, 4:250-263.
202. Aumailley M., Bruckner-Tuderman L., Carter W.G., Deutzmann R., Edgar D., Ekblom P., Engel J., Engvall E., Hohenester E., Jones J.C., Kleinman H.K., Marinkovich M.P., Martin G.R., Mayer U., Meneguzzi G., Miner J.H., Miyazaki K., Patarroyo M., Paulsson M., Quaranta V., Sanes J.R., Sasaki T., Sekiguchi K., Sorokin L.M., Talts J.F., Tryggvason K., Uitto J., Virtanen I., von der Mark K., Wewer U.M., Yamada Y., Yurchenco P.D. A simplified laminin nomenclature. Matrix Biol. 2005, 24:326-332.
203. McLean W.H., Irvine A.D., Hamill K.J., Whittock N.V., Coleman-Campbell C.M., Mellerio J.E., Ashton G.S., Dopping-Hepenstal P.J., Eady R.A., Jamil T., Phillips R., Shabbir S.G., Haroon T.S., Khurshid K., Moore J.E., Page B., Darling J., Atherton D.J., Van Steensel M.A., Munro C.S., Smith F.J., McGrath J.A. An unusual N-terminal deletion of the laminin alpha3a isoform leads to the chronic granulation tissue disorder laryngo-onycho-cutaneous syndrome. Hum. Mol. Genet. 2003, 12:2395-2409.
204. Miner J.H., Yurchenco P.D. Laminin functions in tissue morphogenesis. Annu. Rev. Cell Dev. Biol. 2004, 20:255-284.
205. Willem M., Miosge N., Halfter W., Smyth N., Jannetti I., Burghart E., Timpl R., Mayer U. Specific ablation of the nidogen-binding site in the laminin gamma1 chain interferes with kidney and lung development. Development 2002, 129:2711-2722.
206. Ido H., Ito S., Taniguchi Y., Hayashi M., Sato-Nishiuchi R., Sanzen N., Hayashi Y., Futaki S., Sekiguchi K. Laminin isoforms containing the gamma3 chain are unable to bind to integrins due to the absence of the glutamic acid residue conserved in the C-terminal regions of the gamma1 and gamma2 chains. J. Biol. Chem. 2008, 283:28149-28157.
207. Taniguchi Y., Ido H., Sanzen N., Hayashi M., Sato-Nishiuchi R., Futaki S., Sekiguchi K. The C-terminal region of laminin beta chains modulates the integrin binding affinities of laminins. J. Biol. Chem. 2009, 284:7820-7831.
208. Hallmann R., Horn N., Selg M., Wendler O., Pausch F., Sorokin L.M. Expression and function of laminins in the embryonic and mature vasculature. Physiol. Rev. 2005, 85:979-1000.
209. Helbling-Leclerc A., Zhang X., Topaloglu H., Cruaud C., Tesson F., Weissenbach J., Tome F.M., Schwartz K., Fardeau M., Tryggvason K., et al. Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat. Genet. 1995, 11:216-218.
210. Zenker M., Aigner T., Wendler O., Tralau T., Muntefering H., Fenski R., Pitz S., Schumacher V., Royer-Pokora B., Wuhl E., Cochat P., Bouvier R., Kraus C., Mark K., Madlon H., Dotsch J., Rascher W., Maruniak-Chudek I., Lennert T., Neumann L.M., Reis A. Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum. Mol. Genet. 2004, 13:2625-2632.
211. Kivirikko S., McGrath J.A., Pulkkinen L., Uitto J., Christiano A.M. Mutational hotspots in the LAMB3 gene in the lethal (Herlitz) type of junctional epidermolysis bullosa. Hum. Mol. Genet. 1996, 5:231-237.
212. Muhle C., Jiang Q.J., Charlesworth A., Bruckner-Tuderman L., Meneguzzi G., Schneider H. Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease. Hum. Genet. 2005, 116:33-42.
213. Pulkkinen L., Christiano A.M., Airenne T., Haakana H., Tryggvason K., Uitto J. Mutations in the gamma 2 chain gene (LAMC2) of kalinin/laminin 5 in the junctional forms of epidermolysis bullosa. Nat. Genet. 1994, 6:293-297.
214. Marinkovich M.P. Tumour microenvironment: laminin 332 in squamous-cell carcinoma. Nat. Rev. Cancer 2007, 7:370-380.
215. Tran M., Rousselle P., Nokelainen P., Tallapragada S., Nguyen N.T., Fincher E.F., Marinkovich M.P. Targeting a tumor-specific laminin domain critical for human carcinogenesis. Cancer Res. 2008, 68:2885-2894.
216. Murphy-Ullrich J.E. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?. J. Clin. Invest. 2001, 107:785-790.
217. Bornstein P., Sage E.H. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 2002, 14:608-616.
218. Bornstein P., Agah A., Kyriakides T.R. The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int. J. Biochem. Cell Biol. 2004, 36:1115-1125.
219. Bornstein P. Matricellular proteins: an overview. J. Cell Commun. Signal. 2009, 3:163-165.
220. Murphy-Ullrich J.E., Sage E.H. Revisiting the matricellular concept. Matrix Biol. 2014, 37:1-14.
221. Giachelli C.M., Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000, 19:615-622.
222. Brekken R.A., Sage E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001, 19:816-827.
223. Adams J.C., Lawler J. The thrombospondins. Int. J. Biochem. Cell Biol. 2004, 36:961-968.
224. Hsia H.C., Schwarzbauer J.E. Meet the tenascins: multifunctional and mysterious. J. Biol. Chem. 2005, 280:26641-26644.
225. Frangogiannis N.G. Matricellular proteins in cardiac adaptation and disease. Physiol. Rev. 2012, 92:635-688.
226. Kyriakides T.R., Bornstein P. Matricellular proteins as modulators of wound healing and the foreign body response. Thromb. Haemost. 2003, 90:986-992.
227. Alford A.I., Hankenson K.D. Matricellular proteins: Extracellular modulators of bone development, remodeling, and regeneration. Bone 2006, 38:749-757.
228. Kyriakides T.R., Maclauchlan S. The role of thrombospondins in wound healing, ischemia, and the foreign body reaction. J. Cell Commun. Signal. 2009, 3:215-225.
229. Stenina-Adognravi O. Invoking the power of thrombospondins: regulation of thrombospondins expression. Matrix Biol. 2014, 37:69-82.
230. Stein J.J., Iwuchukwu C., Maier K.G., Gahtan V. Thrombospondin-1-induced vascular smooth muscle cell migration and proliferation are functionally dependent on microRNA-21. Surgery 2014, 155:228-233.
231. Dogar A.M., Semplicio G., Guennewig B., Hall J. Multiple microRNAs derived from chemically synthesized precursors regulate thrombospondin 1 expression. Nucleic Acid Ther. 2014, 24:149-159.
232. Soto-Pantoja D.R., Shih H.B., Maxhimer J.B., Cook K.L., Ghosh A., Isenberg J.S., Roberts D.D. Thrombospondin-1 and CD47 signaling regulate healing of thermal injury in mice. Matrix Biol. 2014, 37:25-34.
233. Dabir P., Marinic T.E., Krukovets I., Stenina O.I. Aryl hydrocarbon receptor is activated by glucose and regulates the thrombospondin-1 gene promoter in endothelial cells. Circ. Res. 2008, 102:1558-1565.
234. Asparuhova M.B., Ferralli J., Chiquet M., Chiquet-Ehrismann R. The transcriptional regulator megakaryoblastic leukemia-1 mediates serum response factor-independent activation of tenascin-C transcription by mechanical stress. FASEB J. 2011, 25:3477-3488.
235. Durvasula R.V., Shankland S.J. Mechanical strain increases SPARC levels in podocytes: implications for glomerulosclerosis. Am. J. Physiol. Renal Physiol. 2005, 289:F577-F584.
236. Chen Y., Leask A., Abraham D.J., Kennedy L., Shi-Wen X., Denton C.P., Black C.M., Verjee L.S., Eastwood M. Thrombospondin 1 is a key mediator of transforming growth factor beta-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism. Fibrogenesis Tissue Repair 2011, 4:9.
237. Kumei Y., Morita S., Katano H., Akiyama H., Hirano M., Oyha K., Shimokawa H. Microgravity signal ensnarls cell adhesion, cytoskeleton, and matrix proteins of rat osteoblasts: osteopontin, CD44, osteonectin, and alpha-tubulin. Ann. N. Y. Acad. Sci. 2006, 1090:311-317.
238. Chiquet-Ehrismann R., Orend G., Chiquet M., Tucker R.P., Midwood K.S. Tenascins in stem cell niches. Matrix Biol. 2014, 37:112-123.
239. Ferrari do Outeiro-Bernstein M.A., Nunes S.S., Andrade A.C., Alves T.R., Legrand C., Morandi V. A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan. Matrix Biol. 2002, 21:311-324.
240. Saito Y., Imazeki H., Miura S., Yoshimura T., Okutsu H., Harada Y., Ohwaki T., Nagao O., Kamiya S., Hayashi R., Kodama H., Handa H., Yoshida T., Fukai F. A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. J. Biol. Chem. 2007, 282:34929-34937.
241. Todorovic V., Chen C.C., Hay N., Lau L.F. The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts. J. Cell Biol. 2005, 171:559-568.
242. Ohkawara B., Glinka A., Niehrs C. Rspo3 binds syndecan 4 and induces Wnt/PCP signaling via clathrin-mediated endocytosis to promote morphogenesis. Dev. Cell 2011, 20:303-314.
243. Godyna S., Liau G., Popa I., Stefansson S., Argraves W.S. Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1. J. Cell Biol. 1995, 129:1403-1410.
244. Segarini P.R., Nesbitt J.E., Li D., Hays L.G., Yates J.R., Carmichael D.F. The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor is a receptor for connective tissue growth factor. J. Biol. Chem. 2001, 276:40659-40667.
245. Mason R.M. Fell-Muir lecture: Connective tissue growth factor (CCN2) -- a pernicious and pleiotropic player in the development of kidney fibrosis. Int. J. Exp. Pathol. 2013, 94:1-16.
246. Eroglu C., Allen N.J., Susman M.W., O'Rourke N.A., Park C.Y., Ozkan E., Chakraborty C., Mulinyawe S.B., Annis D.S., Huberman A.D., Green E.M., Lawler J., Dolmetsch R., Garcia K.C., Smith S.J., Luo Z.D., Rosenthal A., Mosher D.F., Barres B.A. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009, 139:380-392.
247. Midwood K., Sacre S., Piccinini A.M., Inglis J., Trebaul A., Chan E., Drexler S., Sofat N., Kashiwagi M., Orend G., Brennan F., Foxwell B. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat. Med. 2009, 15:774-780.
248. Sadvakassova G., Dobocan M.C., Congote L.F. Osteopontin and the C-terminal peptide of thrombospondin-4 compete for CD44 binding and have opposite effects on CD133+ cell colony formation. BMC Res. Notes 2009, 2:215.
249. Shevde L.A., Das S., Clark D.W., Samant R.S. Osteopontin: an effector and an effect of tumor metastasis. Curr. Mol. Med. 2010, 10:71-81.
250. Schiemann B.J., Neil J.R., Schiemann W.P. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol. Biol. Cell 2003, 14:3977-3988.
251. Nozaki M., Sakurai E., Raisler B.J., Baffi J.Z., Witta J., Ogura Y., Brekken R.A., Sage E.H., Ambati B.K., Ambati J. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J. Clin. Invest. 2006, 116:422-429.
252. Garg P., Yang S., Liu A., Pallero M.A., Buchsbaum D.J., Mosher D.F., Murphy-Ullrich J.E., Goldblum S.E. Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 301:L79-L90.
253. Lynch J.M., Maillet M., Vanhoutte D., Schloemer A., Sargent M.A., Blair N.S., Lynch K.A., Okada T., Aronow B.J., Osinska H., Prywes R., Lorenz J.N., Mori K., Lawler J., Robbins J., Molkentin J.D. A thrombospondin-dependent pathway for a protective ER stress response. Cell 2012, 149:1257-1268.
254. Duquette M., Nadler M., Okuhara D., Thompson J., Shuttleworth T., Lawler J. Members of the thrombospondin gene family bind stromal interaction molecule 1 and regulate calcium channel activity. Matrix Biol. 2014, 37:15-24.
255. Ambily A., Kaiser W.J., Pierro C., Chamberlain E.V., Li Z., Jones C.I., Kassouf N., Gibbins J.M., Authi K.S. The role of plasma membrane STIM1 and Ca(2+)entry in platelet aggregation. STIM1 binds to novel proteins in human platelets. Cell. Signal. 2014, 26:502-511.
256. Zohar R., Suzuki N., Suzuki K., Arora P., Glogauer M., McCulloch C.A., Sodek J. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J. Cell. Physiol. 2000, 184:118-130.
257. Emerson R.O., Sage E.H., Ghosh J.G., Clark J.I. Chaperone-like activity revealed in the matricellular protein SPARC. J. Cell. Biochem. 2006, 98:701-705.
258. Chlenski A., Liu S., Baker L.J., Yang Q., Tian Y., Salwen H.R., Cohn S.L. Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. Cancer Res. 2004, 64:7420-7425.
259. Wong G.S., Rustgi A.K. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br. J. Cancer 2013, 108:755-761.
260. Yan W., Shao R. Transduction of a mesenchyme-specific gene periostin into 293 T cells induces cell invasive activity through epithelial-mesenchymal transformation. J. Biol. Chem. 2006, 281:19700-19708.
261. Beiter K., Hiendlmeyer E., Brabletz T., Hlubek F., Haynl A., Knoll C., Kirchner T., Jung A. beta-Catenin regulates the expression of tenascin-C in human colorectal tumors. Oncogene 2005, 24:8200-8204.
262. Robert G., Gaggioli C., Bailet O., Chavey C., Abbe P., Aberdam E., Sabatie E., Cano A., Garcia de Herreros A., Ballotti R., Tartare-Deckert S. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res. 2006, 66:7516-7523.
263. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
264. Chlenski A., Cohn S.L. Modulation of matrix remodeling by SPARC in neoplastic progression. Semin. Cell Dev. Biol. 2010, 21:55-65.
265. Sarkar S., Nuttall R.K., Liu S., Edwards D.R., Yong V.W. Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res. 2006, 66:11771-11780.
266. Takafuji V., Forgues M., Unsworth E., Goldsmith P., Wang X.W. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007, 26:6361-6371.
267. Puente X.S., Sanchez L.M., Overall C.M., Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 2003, 4:544-558.
268. Overall C.M., Tam E.M., Kappelhoff R., Connor A., Ewart T., Morrison C.J., Puente X., Lopez-Otin C., Seth A. Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol. Chem. 2004, 385:493-504.
269. Puente X.S., Lopez-Otin C. A genomic analysis of rat proteases and protease inhibitors. Genome Res. 2004, 14:609-622.
270. Lopez-Otin C., Bond J.S. Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 2008, 283:30433-30437.
271. Turk B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 2006, 5:785-799.
272. Nagase H. Metalloproteases. Current protocols in protein science / editorial board 2001, Chapter 21. (Unit 21 24). J.E. Coligan (Ed.).
273. Rawlings N.D., Barrett A.J., Bateman A. MEROPS: the peptidase database. Nucleic Acids Res. 2010, 38:D227-D233.
274. Sterchi E.E. Special issue: metzincin metalloproteinases. Mol. Asp. Med. 2008, 29:255-257.
275. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol. Asp. Med. 2008, 29:258-289.
276. Blobel C.P., Wolfsberg T.G., Turck C.W., Myles D.G., Primakoff P., White J.M. A potential fusion peptide and an integrin ligand domain in a protein active in sperm-egg fusion. Nature 1992, 356:248-252.
277. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92:827-839.
278. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006, 69:562-573.
279. Gomis-Ruth F.X. Catalytic domain architecture of metzincin metalloproteases. J. Biol. Chem. 2009, 284:15353-15357.
280. van Goor H., Melenhorst W.B., Turner A.J., Holgate S.T. Adamalysins in biology and disease. J. Pathol. 2009, 219:277-286.
281. Tousseyn T., Jorissen E., Reiss K., Hartmann D. (Make) stick and cut loose--disintegrin metalloproteases in development and disease. Birth Defects Res. C Embryo Today 2006, 78:24-46.
282. Fadnes B., Hadler-Olsen E., Sylte I., Uhlin-Hansen L., Winberg J.-O. 4.4 Matrix metalloproteinase complexes and their biological significance. Extracellular Matrix: Pathobiology and Signaling 2012.
283. Fields G.B. New strategies for targeting matrix metalloproteinases. Matrix Biol. 2015, 44-46C:239-246.
284. Hadler-Olsen E., Fadnes B., Sylte I., Uhlin-Hansen L., Winberg J.O. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011, 278:28-45.
285. Nissinen L., Kahari V.M. Matrix metalloproteinases in inflammation. Biochim. Biophys. Acta 2014, 1840:2571-2580.
286. Vihinen P., Kahari V.M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 2002, 99:157-166.
287. Butler G.S., Overall C.M. Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics. Biochemistry 2009, 48:10830-10845.
288. Rodriguez D., Morrison C.J., Overall C.M. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta 2010, 1803:39-54.
289. Stahtea X.N., Roussidis A.E., Kanakis I., Tzanakakis G.N., Chalkiadakis G., Mavroudis D., Kletsas D., Karamanos N.K. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Int. J. Cancer 2007, 121:2808-2814.
290. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278:16-27.
291. Pytliak M., Vargova V., Mechirova V. Matrix metalloproteinases and their role in oncogenesis: a review. Onkologie 2012, 35:49-53.
292. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: they're not just for matrix anymore!. Curr. Opin. Cell Biol. 2001, 13:534-540.
293. Gialeli C., Theocharis A.D., Kletsas D., Tzanakakis G.N., Karamanos N.K. Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab. Investig. New Drugs 2013, 31:516-524.
294. Bouris P., Skandalis S.S., Piperigkou Z., Afratis N., Karamanou K., Aletras A.J., Moustakas A., Theocharis A.D., Karamanos N.K. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biol. 2015, 43:42-60.
295. Law R.H., Abu-Ssaydeh D., Whisstock J.C. New insights into the structure and function of the plasminogen/plasmin system. Curr. Opin. Struct. Biol. 2013, 23:836-841.
296. Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 1985, 41:657-663.
297. Syrovets T., Lunov O., Simmet T. Plasmin as a proinflammatory cell activator. J. Leukoc. Biol. 2012, 92:509-519.
298. Svineng G., Magnussen S., Hadler-Olsen E. Plasmin and the plasminogen activator system in health and disease. Extracellular Matrix: Pathobiology and Signaling 2012, 261-290. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
299. Hildenbrand R., Allgayer H., Marx A., Stroebel P. Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin. Investig. Drugs 2010, 19:641-652.
300. Gebbink M.F. Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis. J. Thromb. Haemost. 2011, 9(Suppl. 1):174-181.
301. Ye S., Goldsmith E.J. Serpins and other covalent protease inhibitors. Curr. Opin. Struct. Biol. 2001, 11:740-745.
302. Kwaan H., McMahon B. The role of plasminogen-plasmin system in cancer. Coagulation in Cancer 2009, 43-66. Springer, US. H.C. Kwaan, D. Green (Eds.).
303. Smith H.W., Marshall C.J. Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 2010, 11:23-36.
304. Lecaille F., Kaleta J., Bromme D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 2002, 102:4459-4488.
305. Turk V., Stoka V., Vasiljeva O., Renko M., Sun T., Turk B., Turk D. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta 2012, 1824:68-88.
306. Turk V., Turk B., Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001, 20:4629-4633.
307. Vasiljeva O., Reinheckel T., Peters C., Turk D., Turk V., Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 2007, 13:387-403.
308. Goulet B., Baruch A., Moon N.S., Poirier M., Sansregret L.L., Erickson A., Bogyo M., Nepveu A. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell 2004, 14:207-219.
309. Puri N., Roche P.A. Mast cells possess distinct secretory granule subsets whose exocytosis is regulated by different SNARE isoforms. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2580-2585.
310. Reiser J., Oh J., Shirato I., Asanuma K., Hug A., Mundel T.M., Honey K., Ishidoh K., Kominami E., Kreidberg J.A., Tomino Y., Mundel P. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J. Biol. Chem. 2004, 279:34827-34832.
311. Sever S., Altintas M.M., Nankoe S.R., Moller C.C., Ko D., Wei C., Henderson J., del Re E.C., Hsing L., Erickson A., Cohen C.D., Kretzler M., Kerjaschki D., Rudensky A., Nikolic B., Reiser J. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J. Clin. Invest. 2007, 117:2095-2104.
312. Wartmann T., Mayerle J., Kahne T., Sahin-Toth M., Ruthenburger M., Matthias R., Kruse A., Reinheckel T., Peters C., Weiss F.U., Sendler M., Lippert H., Schulz H.U., Aghdassi A., Dummer A., Teller S., Halangk W., Lerch M.M. Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice. Gastroenterology 2010, 138:726-737.
313. Deal C. Potential new drug targets for osteoporosis. Nat. Clin. Pract. Rheumatol. 2009, 5:20-27.
314. Stoch S.A., Wagner J.A. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin. Pharmacol. Ther. 2008, 83:172-176.
315. Funkelstein L., Toneff T., Mosier C., Hwang S.R., Beuschlein F., Lichtenauer U.D., Reinheckel T., Peters C., Hook V. Major role of cathepsin L for producing the peptide hormones ACTH, beta-endorphin, and alpha-MSH, illustrated by protease gene knockout and expression. J. Biol. Chem. 2008, 283:35652-35659.
316. Honey K., Rudensky A.Y. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 2003, 3:472-482.
317. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
318. Takagi J., Strokovich K., Springer T.A., Walz T. Structure of integrin alpha5beta1 in complex with fibronectin. EMBO J. 2003, 22:4607-4615.
319. Hinz B., McCulloch C.A. Integrin function in heart fibrosis: mechanical strain, transforming growth factor-beta 1 activation, and collagen glycation. Extracellular Matrix: Pathobiology and Signaling 2012, 406-431. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
320. Farndale R.W., Lisman T., Bihan D., Hamaia S., Smerling C.S., Pugh N., Konitsiotis A., Leitinger B., de Groot P.G., Jarvis G.E., Raynal N. Cell-collagen interactions: the use of peptide Toolkits to investigate collagen-receptor interactions. Biochem. Soc. Trans. 2008, 36:241-250.
321. Orgel J.P., San Antonio J.D., Antipova O. Molecular and structural mapping of collagen fibril interactions. Connect. Tissue Res. 2011, 52:2-17.
322. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
323. Vogel W. Discoidin domain receptors: structural relations and functional implications. FASEB J. 1999, 13:S77-S82. (Suppl.).
324. Vogel W., Gish G.D., Alves F., Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol. Cell 1997, 1:13-23.
325. Vogel W.F., Abdulhussein R., Ford C.E. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell. Signal. 2006, 18:1108-1116.
326. Leitinger B. Transmembrane collagen receptors. Annu. Rev. Cell Dev. Biol. 2011, 27:265-290.
327. Rocca A.S., Bendeck M.P. Discoidin domain receptors: non-integrin collagen receptors on the move. Extracellular Matrix: Pathobiology and Signaling 2012, 451-466. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
328. Shintani Y., Fukumoto Y., Chaika N., Svoboda R., Wheelock M.J., Johnson K.R. Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J. Cell Biol. 2008, 180:1277-1289.
329. Yeh Y.C., Wang C.Z., Tang M.J. Discoidin domain receptor 1 activation suppresses alpha2beta1 integrin-dependent cell spreading through inhibition of Cdc42 activity. J. Cell. Physiol. 2009, 218:146-156.
330. Wang C.Z., Su H.W., Hsu Y.C., Shen M.R., Tang M.J. A discoidin domain receptor 1/SHP-2 signaling complex inhibits alpha2beta1-integrin-mediated signal transducers and activators of transcription 1/3 activation and cell migration. Mol. Biol. Cell 2006, 17:2839-2852.
331. Yang S.H., Baek H.A., Lee H.J., Park H.S., Jang K.Y., Kang M.J., Lee D.G., Lee Y.C., Moon W.S., Chung M.J. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol. Rep. 2010, 24:311-319.
332. Puré E. CD44: a sensor of tissue damage critical for restoring homeostasis. Extracellular Matrix: Pathobiology and Signaling 2012, 484-498. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
333. Misra S., Heldin P., Hascall V.C., Karamanos N.K., Skandalis S.S., Markwald R.R., Ghatak S. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011, 278:1429-1443.
334. Ponta H., Sherman L., Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003, 4:33-45.
335. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur. J. Cancer 2010, 46:1271-1277.
336. Kozlova I., Ruusala A., Voytyuk O., Skandalis S.S., Heldin P. IQGAP1 regulates hyaluronan-mediated fibroblast motility and proliferation. Cell. Signal. 2012, 24:1856-1862.
337. Skandalis S.S., Kozlova I., Engstrom U., Hellman U., Heldin P. Proteomic identification of CD44 interacting proteins. IUBMB Life 2010, 62:833-840.
338. Bourguignon L.Y., Zhu H., Shao L., Zhu D., Chen Y.W. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil. Cytoskeleton 1999, 43:269-287.
339. Bourguignon L.Y., Zhu H., Shao L., Chen Y.W. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J. Biol. Chem. 2000, 275:1829-1838.
340. Bourguignon L.Y., Singleton P.A., Zhu H., Zhou B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J. Biol. Chem. 2002, 277:39703-39712.
341. Bourguignon L.Y., Zhu H., Shao L., Chen Y.W. CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration. J. Biol. Chem. 2001, 276:7327-7336.
342. Pure E., Cuff C.A. A crucial role for CD44 in inflammation. Trends Mol. Med. 2001, 7:213-221.
343. Naor D., Nedvetzki S., Golan I., Melnik L., Faitelson Y. CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 2002, 39:527-579.
344. Katoh S., Zheng Z., Oritani K., Shimozato T., Kincade P.W. Glycosylation of CD44 negatively regulates its recognition of hyaluronan. J. Exp. Med. 1995, 182:419-429.
345. Skelton T.P., Zeng C., Nocks A., Stamenkovic I. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J. Cell Biol. 1998, 140:431-446.
346. Rochman M., Moll J., Herrlich P., Wallach S.B., Nedvetzki S., Sionov R.V., Golan I., Ish-Shalom D., Naor D. The CD44 receptor of lymphoma cells: structure-function relationships and mechanism of activation. Cell Adhes. Commun. 2000, 7:331-347.
347. Greve B., Kelsch R., Spaniol K., Eich H.T., Gotte M. Flow cytometry in cancer stem cell analysis and separation. Cytometry A 2012, 81:284-293.
348. Chin L., Andersen J.N., Futreal P.A. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 2011, 17:297-303.
349. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
350. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
351. Seo B.R., Delnero P., Fischbach C. In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer. Adv. Drug Deliv. Rev. 2014, 69-70:205-216.
352. Skandalis S.S., Gialeli C., Afratis N., Aletras A.J., Tsegenidis T., Theocharis A.D., Karamanos N.K. Pharmacological targeting of proteoglycans and metalloproteinases: an emerging aspect in cancer treatment. Extracellular Matrix: Pathobiology and Signaling 2012, 785-801. Walter de Gruyter GmbH & Co. KG, Berlin/Boston. N.K. Karamanos (Ed.).
353. Khawar I.A., Kim J.H., Kuh H.J. Improving drug delivery to solid tumors: priming the tumor microenvironment. J. Control Release 2015, 201:78-89.
354. Anderson A.R., Weaver A.M., Cummings P.T., Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006, 127:905-915.
355. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013, 31:2205-2218.
356. Ma J., Chen C.S., Blute T., Waxman D.J. Antiangiogenesis enhances intratumoral drug retention. Cancer Res. 2011, 71:2675-2685.
357. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
358. Klosowska-Wardega A., Hasumi Y., Burmakin M., Ahgren A., Stuhr L., Moen I., Reed R.K., Rubin K., Hellberg C., Heldin C.H. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One 2009, 4.
359. Rosca E.V., Koskimaki J.E., Rivera C.G., Pandey N.B., Tamiz A.P., Popel A.S. Anti-angiogenic peptides for cancer therapeutics. Curr. Pharm. Biotechnol. 2011, 12:1101-1116.
360. Ritchie J.P., Ramani V.C., Ren Y., Naggi A., Torri G., Casu B., Penco S., Pisano C., Carminati P., Tortoreto M., Zunino F., Vlodavsky I., Sanderson R.D., Yang Y. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin. Cancer Res. 2011, 17:1382-1393.
361. Barry-Hamilton V., Spangler R., Marshall D., McCauley S., Rodriguez H.M., Oyasu M., Mikels A., Vaysberg M., Ghermazien H., Wai C., Garcia C.A., Velayo A.C., Jorgensen B., Biermann D., Tsai D., Green J., Zaffryar-Eilot S., Holzer A., Ogg S., Thai D., Neufeld G., Van Vlasselaer P., Smith V. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat. Med. 2010, 16:1009-1017.
362. Liao S., Liu J., Lin P., Shi T., Jain R.K., Xu L. TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin. Cancer Res. 2011, 17:1415-1424.
363. Liu J., Liao S., Diop-Frimpong B., Chen W., Goel S., Naxerova K., Ancukiewicz M., Boucher Y., Jain R.K., Xu L. TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:16618-16623.
364. Jacobetz M.A., Chan D.S., Neesse A., Bapiro T.E., Cook N., Frese K.K., Feig C., Nakagawa T., Caldwell M.E., Zecchini H.I., Lolkema M.P., Jiang P., Kultti A., Thompson C.B., Maneval D.C., Jodrell D.I., Frost G.I., Shepard H.M., Skepper J.N., Tuveson D.A. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013, 62:112-120.
365. Blanquer S.B., Grijpma D.W., Poot A.A. Delivery systems for the treatment of degenerated intervertebral discs. Adv. Drug Deliv. Rev. 2015, 84:172-187.
366. Martino M.M., Briquez P.S., Maruyama K., Hubbell J.A. Extracellular matrix-inspired growth factor delivery systems for bone regeneration. Adv. Drug Deliv. Rev. 2015, 94:41-52.
367. Martino M.M., Tortelli F., Mochizuki M., Traub S., Ben-David D., Kuhn G.A., Muller R., Livne E., Eming S.A., Hubbell J.A. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci. Transl. Med. 2011, 3:100ra189.
368. Kidd K.R., Dal Ponte D., Stone A.L., Hoying J.B., Nagle R.B., Williams S.K. Stimulated endothelial cell adhesion and angiogenesis with laminin-5 modification of expanded polytetrafluoroethylene. Tissue Eng. 2005, 11:1379-1391.
369. Kidd K.R., Williams S.K. Laminin-5-enriched extracellular matrix accelerates angiogenesis and neovascularization in association with ePTFE. J. Biomed. Mater. Res. A 2004, 69:294-304.
370. Min S.K., Lee S.C., Hong S.D., Chung C.P., Park W.H., Min B.M. The effect of a laminin-5-derived peptide coated onto chitin microfibers on re-epithelialization in early-stage wound healing. Biomaterials 2010, 31:4725-4730.
371. Ikemoto S., Mochizuki M., Yamada M., Takeda A., Uchinuma E., Yamashina S., Nomizu M., Kadoya Y. Laminin peptide-conjugated chitosan membrane: Application for keratinocyte delivery in wounded skin. J. Biomed. Mater. Res. A 2006, 79:716-722.
372. Alcaraz L.B., Exposito J.Y., Chuvin N., Pommier R.M., Cluzel C., Martel S., Sentis S., Bartholin L., Lethias C., Valcourt U. Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-beta. J. Cell Biol. 2014, 205:409-428.
373. Tuck A.B., Hota C., Wilson S.M., Chambers A.F. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 2003, 22:1198-1205.
374. Du J., Takeuchi H., Leonhard-Melief C., Shroyer K.R., Dlugosz M., Haltiwanger R.S., Holdener B.C. O-fucosylation of thrombospondin type 1 repeats restricts epithelial to mesenchymal transition (EMT) and maintains epiblast pluripotency during mouse gastrulation. Dev. Biol. 2010, 346:25-38.
375. Shevde L.A., Samant R.S. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014, 37:131-141.
376. Yan Q., Clark J.I., Wight T.N., Sage E.H. Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice. J. Cell Sci. 2002, 115:2747-2756.
377. Martinek N., Shahab J., Saathoff M., Ringuette M. Haemocyte-derived SPARC is required for collagen-IV-dependent stability of basal laminae in Drosophila embryos. J. Cell Sci. 2008, 121:1671-1680.